BDBM476866 US10870660, Compound II-053

SMILES: Cc1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)s1

InChI Key: InChIKey=HNKSCJOZAQWYMZ-QAQDUYKDSA-N

Data: 2 KI

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 476866   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476866 (US10870660, Compound II-053) Show SMILES Cc1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)s1 |r,wU:12.12,wD:9.8,(13.21,2.4,;11.67,2.4,;10.77,1.16,;9.3,1.63,;9.3,3.17,;7.97,3.94,;6.63,3.17,;6.63,1.63,;5.3,3.94,;3.97,3.17,;2.63,3.94,;1.3,3.17,;1.3,1.63,;-.03,.86,;-1.37,1.63,;-2.7,.86,;-3.91,1.82,;-5.41,1.48,;-6.08,.09,;-7.6,-.12,;-7.88,-1.63,;-9.21,-2.4,;-10.54,-1.63,;-11.88,-2.4,;-11.88,-3.94,;-13.21,-1.63,;-13.21,-3.17,;-6.52,-2.36,;-5.41,-1.3,;-3.91,-1.64,;-2.7,-.68,;2.63,.86,;3.97,1.63,;10.77,3.65,)| Show InChI InChI=1S/C23H31F3N4O2S2/c1-15-27-13-18(33-15)12-21(31)28-17-4-2-16(3-5-17)6-9-30-10-7-19-20(8-11-30)34-22(29-19)32-14-23(24,25)26/h13,16-17H,2-12,14H2,1H3,(H,28,31)/t16-,17-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0670	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020)
					More data for this Ligand-Target Pair
D(2) dopamine receptor (Homo sapiens (Human))	BDBM476866 (US10870660, Compound II-053) Show SMILES Cc1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)s1 |r,wU:12.12,wD:9.8,(13.21,2.4,;11.67,2.4,;10.77,1.16,;9.3,1.63,;9.3,3.17,;7.97,3.94,;6.63,3.17,;6.63,1.63,;5.3,3.94,;3.97,3.17,;2.63,3.94,;1.3,3.17,;1.3,1.63,;-.03,.86,;-1.37,1.63,;-2.7,.86,;-3.91,1.82,;-5.41,1.48,;-6.08,.09,;-7.6,-.12,;-7.88,-1.63,;-9.21,-2.4,;-10.54,-1.63,;-11.88,-2.4,;-11.88,-3.94,;-13.21,-1.63,;-13.21,-3.17,;-6.52,-2.36,;-5.41,-1.3,;-3.91,-1.64,;-2.7,-.68,;2.63,.86,;3.97,1.63,;10.77,3.65,)| Show InChI InChI=1S/C23H31F3N4O2S2/c1-15-27-13-18(33-15)12-21(31)28-17-4-2-16(3-5-17)6-9-30-10-7-19-20(8-11-30)34-22(29-19)32-14-23(24,25)26/h13,16-17H,2-12,14H2,1H3,(H,28,31)/t16-,17-	PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	730	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020)
					More data for this Ligand-Target Pair